EMA Withdrawn: Ritemvia (rituximab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA withdrawal of Ritemvia (rituximab) by Celltrion Healthcare Hungary Kft., affecting indications in lymphoma (non-Hodgkin) and vasculitic diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Microscopic Polyangiitis
• Non-hodgkin Lymphoma
• Wegener Granulomatosis

Drugs mentioned

• Ritemvia (rituximab)

Snippet

Status: Withdrawn. Therapeutic area: Lymphoma, Non-Hodgkin;Microscopic Polyangiitis;Wegener Granulomatosis. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 09/10/2020